Abstract | The involvement of autoreactive T cells in the pathogenesis of rheumatoid arthritis (RA) as well as in autoimmune animal models of arthritis has been well established; however, unanswered questions, such as the role of joint-homing T cells, remain. Animal models of arthritis are superb experimental tools in demonstrating how T cells trigger joint inflammation, and thus can help to further our knowledge of disease mechanisms and potential therapies. In this Review, we discuss the similarities and differences in T-cell subsets and functions between RA and mouse arthritis models. For example, various T-cell subsets are involved in both human and mouse arthritis, but differences might exist in the cytokine regulation and plasticity of these cells. With regard to joint-homing T cells, an abundance of synovial T cells is present in humans compared with mice. On the other hand, local expansion of type 17 T-helper (T H 17) cells is observed in some animal models, but not in RA. Finally, whereas T-cell depletion therapy essentially failed in RA, antibody targeting of T cells can work, at least preventatively, in most arthritis models. Clearly, additional human and animal studies are needed to fill the gap in our understanding of the specific contribution of T-cell subsets to arthritis in mice and men.
Introduction
"Arthritis: where are the T cells?" This question was raised by Kamradt and Frey in an editorial in a 2010 issue of Arthritis Research & Therapy. 1 In their commentary, Kamradt and Frey referred to our study in which only a minuscule population of T cells was found in the joints of mice with proteoglycan-induced arthritis (PGIA). 2 In the same study, depletion of T cells from the peripheral blood of mice, which led to a reduction of T-cell numbers in the synovial fluid, failed to diminish joint inflammation. 2 This observation raises a more general question: how closely do animal models resemble human rheumatoid arthritis (RA)? Certainly a major, and clinically relevant, question is why T-cell depletion strategies failed therapeutically in RA, whereas most worked preventatively, but in some models also therapeutically, in mouse arthritis. RA is an autoimmune inflammatory rheumatic disease characterized by synovitis of multiple joints eventually leading to cartilage and bone destruction. 3 Although RA is a T-cell-dependent disease, no definitive 'arthritogenic' T-cell populations have been characterized to date. Impaired immune regulation, resulting from deficiencies in the number and/or function of regulatory T (T REG ) cells, and/or the resistance of effector T (T EFF ) cells to T REG -cell-mediated suppression, is likely to be involved in the development of synovial inflammation. 4 Furthermore, in addition to the 'loss of control' within the inflammatory environment, autoreactive T cells outside the joints and autoantibodies generated via T-cell-dependent processes are key players in the pathogenesis of RA. 3 Animal models are needed for in-depth investigation of pathogenic pathways that are involved in RA but that cannot be adequately investigated in humans. 5 For example, animals can be subjected to experimental procedures such as arthritis-inducing immunizations, cell depletion or transfer, selective cross-breeding, genetic manipulations, in vivo cell-homing studies and, most importantly, numerous preventative and therapeutic targeting strategies, most of which cannot be carried out in humans. Numerous arthritis models have been well characterized. [5] [6] [7] In past decades, we have personally obtained considerable amounts of information about the function of T-cell subsets that drive the pathogenic processes in the mouse PGIA model, in particular. [7] [8] [9] Here, we provide a review of our current understanding of autoreactive T cells, various T-cell subsets, jointhoming T cells and T-cell-dependent autoantibody production in arthritis. We briefly present data obtained in human RA and compare these findings with those obtained from studies in animal models of arthritis. As our greatest expertise is in PGIA, we focus primarily on this model. However, some studies performed in other inducible arthritis models, such as type II collagen (CII)-induced arthritis (CIA) and glucose-6-phosphate isomerase (G6PI)-induced arthritis, as well as in spontaneous arthritis in K/BxN or SKG mice, are also discussed. Finally, we touch on the question as to why most T-cell-targeting therapies failed in patients with RA and how suitable animal models are in predicting the clinical efficacy of T-cell-directed biologic agents in RA.
Rise and persistence of autoreactive T cells
The importance of T cells in arthritis T cells have various roles in RA and in mouse models of the disease; the major similarities and differences between human and mouse disease with respect to T cells are summarized in Table 1 . Several lines of evidence suggest that, similarly to in human RA, T cells have a critical role in inducible animal models of arthritis, including PGIA and CIA, as well as in spontaneous arthritis in K/BxN and SKG mice. 6, 7, 10 T cells are also involved in the generation of 'arthritogenic' anti bodies that can passively transfer arthritis after injection into naive mice. 6, 7 In PGIA, T-cell depletion using anti-CD4 antibodies led to complete inhibition of arthritis develop ment, whereas treatment with anti-CD8 antibodies resulted in increased disease severity.
11 As CD8 + T REG cells exist in human RA, 4 depletion of these cells by anti-CD8 antibodies might indeed result in aggravation of the disease. CD4-depleting antibodies also suppressed CIA when administered before, but not after, arthritis development, suggesting a greater role of T helper (T H ) cells in the initiation phase of the disease than in the effector phase. 12 In the same study, in vivo activated CD4 + T cells specific for CII were found to be moderately resistant to antibody-mediated depletion. 12 Thus, this finding could, at least in part, explain why most anti-CD4 antibody studies in human RA have failed. In adoptively transferred PGIA and CIA, which are induced in naive mice by the transfer of immune cells from mice with PGIA or CIA, removal of CD3 + T cells (that is, all T cells) or CD4 + T cells from the donor population inhibited the transfer of arthritis to severe combined immunodeficient (SCID) mice (which lack functional B and T cells). 2, 13 Therapeutic depletion of CD4 + cells (that is, after onset of arthritis) abrogated G6PI-induced arthritis.
14 Together, these findings suggest that CD4 + T cells possibly have an important role in the development of arthritis in various mouse models. Their involvement might be crucial in the early phase of the disease, suggesting that anti-CD4 antibody therapy could be effective early in the disease course.
Abnormal T-cell selection Abnormal T-cell selection and low T-cell signalling capacity might have a role in the development of autoimmune arthritis. Normally, most self-reactive T cells are deleted in the thymus during their development Key points ■ Autoreactive T cells have an important role in the pathogenesis of both rheumatoid arthritis (RA) and mouse models of the disease ■ In addition to similarities, some differences exist in the regulation of the development and plasticity of type 1 and type 17 T-helper cell and regulatory T-cell subsets in humans and mice ■ The contribution of joint-homing T cells to local inflammation in arthritis is not clear in either species ■ Unlike in mouse arthritis, most T-cell-targeting therapeutic strategies failed in RA; only a few of them (such as abatacept) succeeded ■ Anti-cytokine and anti-B-cell therapies might indirectly suppress pathogenic T cells in human and mouse arthritis or are deleted or suppressed in the periphery. In SKG mice, however, a point mutation in the gene encoding ZAP70, a tyrosine kinase involved in T-cell receptor (TCR) signal transduction, results in aberrant TCR signalling, which might enable self-reactive T cells to escape thymic deletion. 15 Such self-reactive T cells (of as-yet-unknown antigen specificity) are thus thought to drive the development of spontaneous autoimmune arthritis in SKG mice, which have an arthritis-prone BALB/c background. 10 Similarly, in humans, RA and other autoimmune diseases such as SLE and systemic sclerosis have also been associated with low signalling capacity of self-reactive T cells, which might protect these cells against negative selection.
15,16
Autoreactive T-cell activation
MHC restriction of antigen recognition
Antigen presentation to CD4 + T cells is MHC class II restricted. Thus, in both RA and its rodent models (Table 1) , the recognition of particular autoantigens can depend on the MHC class II genotype of the indivi dual. For example, the major T-cell epitope (amino acids 259-273) in CII-an autoantigen that might contribute to autoimmunity in a proportion of patients with RA-is preferentially presented by antigen-presenting cells (APCs) that express HLA-DRB1*04 (HLA-DR4) molecules in RA. 17 Similarly, T-cell responses to citrullinated (deiminated) self-proteins are detected more frequently in patients with RA who express the HLA-DRB1 'shared epitope' (a five-amino-acid sequence present in some HLA-DRB1 alleles) than in those negative for sharedepitope-containing MHC class II molecules. 18 In line with these findings, genetic studies have established that certain HLA-DRB1*01 and HLA-DRB1*04 alleles containing sequences encoding the shared epitope are associated with RA. 19, 20 As in patients with RA, the MHC haplotype (referred to as H2 in mice) is a major determinant of arthritis susceptibility in mouse models. For example, only a few mouse strains are susceptible to PGIA or CIA. 8, 21 More over, PGIA-susceptible BALB/c mice (which have the H2 d haplotype) are resistant to CIA, and conversely CIA-susceptible DBA/1 mice (which have the H2 q haplotype) are resistant to PGIA. 8 An interesting dichotomy of MHC-class-II-dependent T-cell antigen recognition was described in mice carrying a KRN TCR transgene. In the wild-type strains, T cells expressing the transgenic KRN TCR recognize bovine ribonuclease in the context of A k MHC class II molecules; however, when crossed with nonobese diabetic (NOD) mice to generate K/BxN hybrids, KRN-TCR-transgenic T cells recognize the ubiquitous self-antigen G6PI in the context of the MHC class II molecule A g7 , which is derived from the NOD background. 22, 23 These G6PI-specific T cells then provide help to B cells, leading to overproduction of anti-G6PI antibodies and spontaneous arthritis development in K/BxN mice. 22 Not surprisingly, treatment with anti-CD4 antibodies prevented the development of arthritis in this model. 23 Furthermore, transfer of T-cell-depleted K/BxN splenocytes to immunodeficient mice was unable to induce arthritis, also indicating the critical role of autoreactive T cells in the disease process. 22 A number of non-MHC genes related to T cells have also been associated with RA and with mouse models of the disease. These genetic associations are discussed briefly in Box 1.
Autoantigen specificities
Autoreactive T cells can recognize a number of autoantigens in patients with RA, such as various epitopes in CII 17, 24 or the citrullinated form of the 5/4E8 epitope (amino acids 84-103) of the human cartilage proteoglycan aggrecan. 18, 25 Multifunctional T-cell responses directed towards both native and glycosylated variants of the CII 259-273 epitope are sustained during the RA disease course. 17 Furthermore, citrullinated aggrecan induces T-cell responses in patients with RA but not in healthy controls, whereas the non-citrullinated aggrecan epitope does not stimulate such responses. 25 In addition, citrullinated proteins have been detected in fibrin deposits within RA synovial tissue, and citrullinated fibrin could be the major target of anti-filaggrin antibodies in the synovium in vivo. 26 In a comparative study on T-cell responses towards various citrullinated peptides, citrullinated aggrecan was the most immunogenic, especially in patients with RA carrying the HLA-DRB1 shared epitope. 18 Interestingly, a T-cell response to the citrullinated aggrecan epitope (or no response) was detected in early RA, whereas longstanding disease was associated with T-cell responses to citrullinated epitopes of multiple proteins. 18 This varied responsiveness is a good example of epitope spreading, a process involved in the progression of autoimmunity. Such epitope spreading also occurred during sustained T-cell responses to CII. 17 With regard to animal models, mouse CD4 + T-cell lines specific for citrullinated fibrinogen have been found to enhance arthritis severity when transferred to mice with CIA. 27 Furthermore, T-cell responses to the mouse analogue of the citrullinated aggrecan epitope after priming of BALB/c mice with the mouse citrullinated aggrecan peptide were shown to be stronger than responses to the native (noncitrullinated) selfepitope after priming with that peptide. 9 Thus, T-cell responses against citrullinated protein antigens have been identified in both humans and mice.
T-cell clonal expansion
Clonal expansion of CD4 + T cells has been described in patients with RA. 28, 29 Indeed, in one early study of 15 patients with this disease, oligoclonally expanded T cells were identified in the peripheral blood of all the patients, whereas such T-cell subpopulations were found in few healthy controls or patients with other types of arthritis. These 'RA-specific' expanded T-cell subpopulations persisted for years and infiltrated the synovial tissue. 28 Oligoclonal expansion of a unique CD4 + T-cell subset lacking the co-stimulatory molecule CD28 on their surface has also been described in RA. These CD4 + CD28 -T cells have been found to be resistant to apoptosis, which might explain the chronic persistence of the expanded populations in patients with RA. 29 Abbreviations: ACPA, anticitrullinated protein antibodies; CII, type II collagen; NR, not reported; PD1, programmed cell death protein 1; RA, rheumatoid arthritis; RF, rheumatoid factor; STAT3, signal transducer and activator of transcription 3; TGF-β, transforming growth factor β; T FH cell, follicular helper T cell; T H cell, helper T cell; T REG cell, regulatory T cell.
T-cell subsets in arthritis
produce IFN-γ, and a disturbed T H 1-T H 2 balance have been thought to drive organ pathology in RA as well as in other autoimmune diseases. 4, [30] [31] [32] However, the T H 1-cell concept has significantly changed since the discovery of IL-17-producing T H 17 cells. These cells, and IL-17, are major contributors to synovial inflammation, as well as to cartilage and bone damage. 32, 33 T-cell responses to CII and citrullinated aggrecan in RA have been associated with increased production of IFN-γ and IL-17, respectively. 17, 18, 24, 25 Indeed, ex vivo stimulation of RA synovial fluid mononuclear cell populations (containing CII-reactive T cells) with CII resulted in increased production of the T H 1-type cytokines IL-12 and IFN-γ, but not of the T H 2-type cytokine IL-4.
17,24 Moreover, T H 1-cell-associated epigenetic changes, such as demethylation of the IFNG locus, have been detected in CD4 + T-cells from RA synovial fluid. 34 With regard to citPG, ex vivo stimulation of peripheral blood mononuclear cells with this epitope induced proliferative responses of T H 17 cells and prominent IL-17 production in patients with RA. 25 Similarly, another study showed that the proliferative T-cell response to citPG was associated with the release of the T H 17-type cytokines IL-6, IL-17 and TNF. 18 Among animal models of inflammatory arthritis, PGIA has been shown to be a T H 1-cell-driven disease. 35 IFN-γ is necessary for the onset and progression of the disease, and the absence of this cytokine leads to reduced incidence and severity of arthritis and weaker proteoglycan-specific IgG2a antibody responses. 36 Increased IFN-γ levels decrease the number and percentage of activated T REG cells in PGIA. 37 Moreover, compared with the standard protocol for induction of PGIA (in which BALB/c mice are injected with proteoglycan in complete Freund's adjuvant [CFA]), immunization of BALB/c mice with proteoglycan in the synthetic adjuvant dimethyl-dioctadecyl ammonium bromide (DDA) induced a strong T H 1 shift, and this effect led to a somewhat more severe manifestation of PGIA. 38 Conversely, a shift towards a T H 2-type response suppresses PGIA; for example, administration of T H 2-type cytokines, such as IL-4 and IL-10, before the onset of arthritis prevented the development of histopathological changes in the joints and clinical arthritis. 36, 38 IL-4 also inhibited proteoglycan-specific IFN-γ responses and reduced proinflammatory cytokine expression at target sites in PGIA. 35 Furthermore, arthritis was markedly more severe in IL-4-deficient BALB/c mice than in their wild-type counterparts. 36 Substantial T H 17-cell responses have been detected in both human and mouse arthritic joints. 32, 39, 40 T H 17 cells have a crucial role in CIA, as CIA was markedly suppressed in IL-17-deficient mice. 41 Arthritis suppression in these mice was associated with reduced cellular and humoral responses to CII. By contrast, in PGIA, ablation of IL-17 had no effect on inflammatory cell recruitment or bone erosion in the arthritic joints, nor did it affect the generation of proteoglycan-specific T cells and IgG2a antibodies. 42 In a comparative study, immunization of BALB/c mice with proteoglycan in CFA was associated with the dominance of T H 17 over T H 1 cells, whereas the same immunization protocol using DDA adjuvant had the opposite effect. 43 Nonetheless, although T H 1-T H 17 polarization was clearly influenced by the adjuvant used, subset dominance had no significant impact on disease onset or severity. 38, 43 The cytokine regulation of T H 17-cell development and function in human RA and its mouse models are illustrated in Figure 1 and discussed in Box 2.
In RA, the inflamed synovium contains an abundance of T H 1 over T H 17 cells, suggesting that the local expansion of T H 17-cell populations within the arthritic joint is limited. 4, 44 The lower proportion of T H 17 cells might be a result of the epigenetic instability of T H 17-cell chromatin structure, which is key to phenotypic plasticity of this subset. 45 Bifunctional T H 1-T H 17 cells producing both IFN-γ and IL-17 have been identified in RA synovial fluid, but not in peripheral blood. 40, 46 Moreover, in ex vivo cultures, synovial fluid, but not peripheral blood, T H 17 cells produced both IL-17 and IFN-γ. 4, 40 On the other hand, addition of IL-12, a T H 1-cell-promoting cytokine found in RA synovial fluid, enhanced the conversion of peripheral blood T H 17 cells to the T H 1 pheno type. 40 Therefore, T H 17 cells, under the influence of locally produced cytokines such as IL-12, might transform into T H 1-like cells, leading to an increased ratio of T H 1:T H 17 cell numbers at inflammatory sites such as arthritic joints. 4, 40 The developmental plasticity of mouse T H 17 cells, by means of their conversion to the T H 1 phenotype, has been described in in vitro studies and in an animal model of colitis. 47 Whether the inflammatory microenvironment in arthritic mouse joints facilitates the T H 17 to T H 1 cell conversion, as it does in RA, 4, 40 remains to be determined. In addition, mouse T REG cells can be converted into IL-17-secreting cells, indicating plasticity between T H 17 and T REG cells in the mouse system. 32 By contrast, mouse T H 1 and T H 2 cells seem to be phenotypically stable, terminally differentiated subsets. 32 Follicular helper T cells B-cell maturation in germinal centres (GCs) and autoantibody production are regulated by T cells. [48] [49] [50] GC-like structures, which are signs of lymphoid neogenesis, have Box 1 | Associations of T-cell-related genes with RA SNPs within numerous chromosome regions (loci) have been reported in GWAS of patients with RA. Among the >30 confirmed non-HLA loci contributing to RA risk, probably the strongest associations have been found with loci containing the PTPN22 (protein tyrosine phosphatase, non-receptor type 22) and IL23R (IL-23 receptor) genes. In brief, these genes, as well as the CTLA4 (cytotoxic T-lymphocyte antigen 4), CCR6 (CC-chemokine receptor 6) and CD40 alleles that have also been associated with RA, are highly likely to be involved in T-cell function underlying the pathogenesis of RA. 20, 113 SNPs in PADI4 have also been identified in patients with RA. The PADI4 enzyme can catalyse the citrullination of proteins, which then can trigger the production of autoantibodies to citrullinated epitopes in patients with RA. 20, 113 Autoantibody production is highly linked to pathogenic T-cell involvement. Arthritis-associated MHC and non-MHC loci have also been identified in GWAS carried out in CIA and proteoglycan-induced arthritis mouse models. 20, 114 Some of these mouse loci overlap between the two models as well as with RA susceptibility alleles. 20, 114 Abbreviations: CIA, collagen-induced arthritis; GWAS, genome-wide association studies; PADI4, peptidyl arginine deiminase, type IV; RA, rheumatoid arthritis; SNP, single nucleotide polymorphism.
been described in the severely inflamed RA synovium, and these ectopic GCs have been shown to contain CD4 + T cells. 49 However, unlike in severe RA, ectopic lymphoid structures have never been reported in the arthritic mouse synovium.
Within GCs, the fate of B cells is highly dependent on their ability to present antigens to a specialized subset of T cells known as follicular helper T (T FH ) cells. T FH cells uniquely coexpress CXC-chemokine receptor 5 (CXCR5; required for their homing to B-cell follicles) and the inhibitory receptor programmed cell death protein 1 (PD1). 50, 51 They also express the tran scription factor BCL6, a master regulator of T FH -cell function. 50, 51 Through downregulation of IL-2 production, PD1 is thought to help maintain high levels of BCL6 in T FH cells. 51 Within GCs, T FH cells promote the development of high-affinity memory B cells and long-lived plasma cells. Elevated numbers of T FH cells have been associated with RA, 48 and given the critical role of these cells in B-cell activation and antibody production, the failure of T FH cells to maintain self-tolerance and their potential contribution to autoimmunity have drawn much attention. 48, 52, 53 PD1 is abundantly expressed by RA synovial T FH cells, yet these cells are fairly resistant to PD1-PD1 ligand 1 (PDL1)-mediated inhibition of proliferation (Table 1) . 55 The decreased response of synovial T cells to PD1 ligation might be attributable in part to the presence of a soluble isoform of PD1 in RA synovial fluid, which can interfere with, although not completely block, PDL1 binding to these cells. 55 In mice, expansion of T FH cells might occur in the spleen, as observed in Pdl1-deficient BALB/c mice following induction of PGIA.
56 PDL1 regulates autoimmunity by suppressing autoreactive CD4 + T-cell res ponses. In addition, expression of PDL1 on a non-B and non-T cell type promotes B-cell survival by restraining the expansion and activation of T FH cells through interaction with PD1. In the PGIA model, Pdl1-deficient mice exhibited increased autoreactive T H 1-cell responses, as well as an elevated frequency and activation status of T FH cells, which were associated with death of GC B cells in the spleen and worsening of arthritis symptoms. 56 Developmental plasticity of mouse T FH cells has also been described. Early T H 1-cell differentiation was associated with transient appearance of T cells with T FH or dual T H 1-T FH phenotypes. At a later phase of T-cell development, a repression of T FH -cell function that permitted full T H 1-cell differentiation was observed. 57 Such plasticity has not yet been described in RA (Table 1) .
Regulatory T cells
The role of T REG cells and the loss of regulatory control of effector T cells in the pathogenesis of RA has been reviewed in this journal by Wehrens et al., 4 so this issue is only briefly discussed here. Crucially, the resistance of T EFF cells to T REG -cell suppression might be a key explanation for the loss of control and the perpetuation of autoimmune inflammation in RA. The two main populations of T REG cells-thymus-derived 'natural' T REG cells and peripherally induced T REG cells-have both shared and distinct properties, but they can both suppress T EFF cells. In addition to emerging markers distinguishing between them, the signature T REG -cell transcription factor forkhead box P3 (FOXP3) has been shown to be constitutively expressed in thymus-derived T REG cells, whereas its expression requires the presence of TGF-β in peripherally induced T REG cells. 8 In RA, diminished function of thymus-derived T REG cells has been associated with defects in CTLA4-mediated signalling, and disease control via anti-TNF therapy cannot overcome this defect. 59 By contrast, anti-TNF therapy in RA increases the number and function of peripherally induced T REG cells, in a TGF-β-dependent man ner, and these cells seem to be able to suppress pathogenic T cells. [60] [61] [62] T REG cells also have an important role in regulating arthritis in animal models. Transfer of CD4 + CD25 + T REG cells into mice with CIA slowed disease progression and reduced acute-phase protein production, although CII-specific T-cell and antibody responses were not affected. 63 In mice with PGIA that underwent a therapeutic bone marrow transplantation (BMT), 
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Figure 1 | Cytokine regulation of the T H 17-T REG cell axis in human RA and its mouse models. Naive T cells can differentiate into either T H 17 or T REG cells and
there is high plasticity between these T-cell subsets. This figure summarizes inflammatory mediators enabling the differentiation of these T-cell subsets, and those mediators produced by these cells in humans and mice. Similarities and differences between human and mouse arthritis with respect to T-cell subsets are further explained in the main text and in Table 1 . Abbreviations: CCR, CC-chemokine receptor; FOXP3, forkhead box P3; RA, rheumatoid arthritis; ROR, retinoic acid receptor-related orphan receptor; STAT, signal transducer and activator of transcription; TGF-β, transforming growth factor β; T REG cell, regulatory T cell; T H 17 cell, type 17 T helper cell.
CD25 + FOXP3 -memory T REG cells contributed to rapid improvement of arthritis 1 week after BMT, and 3 weeks after BMT FOXP3
+ T REG cells emerged that stabilized the disease at a lower severity level than before BMT. 64 Conversely, depletion of the T REG -cell subset by administration of an anti-CD25 antibody led to severe arthritis in asymptomatic proteoglycan-immunized mice. 64 Moreover, reduced disease severity in PGIA following administration of a B-cell-depleting anti-CD20 antibody, rituximab, was associated with increased numbers of FOXP3 + T REG cells as well as diminished B-cell numbers. 37 Indeed, depletion of these treatment-induced T REG cells using an anti-CD25 antibody restored the severity of PGIA to a level equal to that observed in untreated mice. 37 Although T cells constitute a minor population of cells in the synovial fluid of arthritic K/BxN mice, 45-70% of these T cells belong to the CD25 + FOXP3 + T REG -cell subset. 65 In the absence of T REG cells, for example in K/BxN mice harbouring a loss-of-function mutation in the Foxp3 gene, a higher degree of local destruction in the joints was observed and otherwise unaffected joints also became inflamed. 65 T REG cells seemingly accumulated in the arthritic joints regardless of antigen specificity, as T REG cells were also found in elevated num bers in non-K/BxN animals following passive transfer of arthritis with serum from K/BxN mice. 65 Thus, T REG cells accumulate in arthritic joints through either recruitment or conversion from another phenotype. Such cells might locally suppress T EFF cells; however, as shown in RA, their potency might be reduced in the inflammatory environment.
In both mice and humans, a reciprocal relationship exists in the development of T H 17 and T REG cells, with a high degree of plasticity between these T-cell subsets. 4, [66] [67] [68] Under proinflammatory conditions, such as in the inflamed joint, T H 17-cell development is enhanced by various cytokines, including IL-6, TGF-β and IL-1β, and also potentially through IL-2 consumption by T REG cells. Furthermore, in the inflammatory milieu, a small proportion of unstable peripherally induced T REG cells might be converted into effector T H 17 cells that produce IL-17 ( Figure 1) . 4, 67, 68 In patients with RA treated with TNF antagonists, T REG cells can gain control over T H 17 cells, at least in part, by inhibiting IL-6 production. 62 Of note, some differences exist between mouse and human T REG cells. For example, IL-2 promotes T REG -cell development at the expense of T H 17 cells in mice, but not in humans (Figure 1) . 32 In humans, TNF inhibits T REGcell expansion 4, 69 and, correspondingly, neutralization of this cytokine by anti-TNF biologic agents promotes T REG -cell expansion in patients with RA. 60, 61 Furthermore, in RA, inhibition of TNF by various anti-TNF biologic agents or defective TNFR2 signalling improves the suppressive function of T REG cells. It has been suggested that human T REG -cell function is dependent on the phosphorylation status of FOXP3. In accordance with this hypothesis, TNF-induced FOXP3 dephosphorylation is associated with impaired T REG -cell function, 70 and anti-TNF treatment improves defective T REG -cell function in RA by restoring FOXP3 serine phosphorylation. 70 By contrast, in mice, TNF promotes the expansion of T REG cells 4, 71 and, at least in some studies, TNF neutralization was shown to suppress the function of this subset. 72 Thus, TNF or anti-TNF treatment might have opposite effects on T REG cells in mice and humans. 4 
Joint-homing T cells in arthritis
Phenotype and function As described above, the local inflammatory milieu within the RA joint highly influences the proportion and function of T H 1, T H 17 and T REG -cell subsets. 4 Local enrichment and differentiation of T H 1 and T REG -cell subpopulations is accompanied by a relatively limited local expansion of T H 17 cells within the inflamed synovium, possibly triggered by cells with APC function. 4, 73 Proinflammatory cytokines downregulate FOXP3 expression and stimulate IL-17 production by CD25 + FOXP3 + synovial T REG cells, leading to their differen tiation towards the T H 17-cell phenotype. 4, 74 Yet, T H 17 cells are present in relatively low quantities in the synovial fluid of patients with RA, which might be a consequence of T H 17-cell conversion to the T H 1 pheno type. 39, 40 The inflammatory environment also influences the suppressive function of T REG cells in the RA joint. A substantial population of T REG cells is present in RA synovial fluid, and these cells have the capacity to suppress T EFF cells. However, the presence of proinflammatory mediators in this environment abrogates such suppressor activity. 4, 75 Unlike in RA, T cells constitute a very minor population of joint-homing cells in mouse models includ ing PGIA, 2,76 CIA 77 and K/BxN arthritis. 65 In adop tively transferred PGIA, serial in vivo visualization of fluorochromelabelled donor T cells failed to identify T cells entering the
Box 2 | Cytokine regulation of T H 17-cell differentiation and function
The STAT3-activating cytokine IL-6, in combination with other cytokines described below, is a major inducer of T H 17-cell responses in both mice and humans. 32 It was first shown in mice that TGF-β and IL-6 are the main cytokines involved in the induction of the key T H 17-cell transcription factor RORγt and thus in T H 17-cell development. 32 Although early reports suggested that in RA, unlike in mouse models, TGF-β might not be needed for the development of T H 17 cells, subsequent studies have confirmed that TGF-β is also required for human T H 17-cell differentiation. 66, 67, 115, 116 In RA, TGF-β induces the expression of both RORγt and the key T REG -cell transcription factor FOXP3 in naive T cells and thus stimulates their differentiation into either T H 17 or induced T REG cells, depending on the inflammatory environment. 66, 67, 115, 116 IL-1, which only transiently induces RORγt, also induces T H 17-cell development in humans. 66, 67, 115, 116 Thus, in RA, IL-6 and IL-1, rather than TGF-β, might be the main inducers of T H 17-cell development. However, IL-1 might not be as important in the induction of T H 17 cells in mice, although this cytokine, especially in combination with IL-23, promoted T H 17-cell proliferation in mice deficient of IL-1 receptor antagonist ( Figure 1 , Table 1 ). 110 An IL-21-dependent and STAT3-dependent positive feedback loop exists in mice, in which IL-21 produced by naive T cells promotes T H 17-cell development, and these cells also produce IL-21. 32 This positive IL-21-dependent feedback loop might also be present in RA; 111 indeed, IL-21 is also required for human T H 17-cell differentiation. 115 IL-23, another STAT3-activating cytokine, also supports T H 17-cell polarization in both species. 32 Lastly, IL-2 stimulates the sustained production of the T H 17-cell cytokines IL-17 and IL-22 in RA, and might induce T REG cells at the expense of T H 17 cells in mice (Figure 1 ). 4, 32 Abbreviations: FOXP3, forkhead box P3; RA, rheumatoid arthritis; ROR, retinoic acid receptorrelated orphan receptor; STAT, signal transducer and activator of transcription; TGF-β, transforming growth factor β; T H 17 cell, type 17 helper T cell; T REG , regulatory T cell.
joints of recipient mice, whereas accumulation of donor T cells was readily detectable in the lymph nodes of the host following transfer and during arthritis development. 2 In CIA, introduction of a human RA-susceptibility HLA-DR4 transgene into MHC class II-deficient DBA/1 mice made it possible to identify T cells specific for HLA-DR4-restricted CII 261-273 peptide in the joints ex vivo. 77 These CII-specific CD44 + (activated) T cells were detectable in acutely arthritic joints, but they disappeared from the synovial fluid by 2 weeks after the onset of CIA. Although the phenotype of joint-homing T cells was not investigated in this study, given the preferential attraction of the CD25 + FOXP3
+ subset to sites of inflammation 63, 65 it is possible that the majority of these cells were T REG cells.
Recruitment to the joint Chemokines and their receptors provide directional cues for T-cell migration to lymphoid organs and inflammatory sites. In RA and animal models of arthritis, mostly CC-type chemokines, together with their receptors, are involved in T-cell homing to the joints. 78 Among the CC-type chemokines, CCL2 (also known as MCP1), CCL3 (also known as MIP1α), CCL5 (also known as RANTES), CCL7 (also known as MCP3), CCL8 (also known as MCP2), CCL13 (also known as MCP4), CCL17 (also known as TARC), CCL18 (also known as PARC), CCL19 (also known as ELC), CCL20 (also known as MIP3α) and CCL21 (also known as SLC) have all been detected in the sera and joints of patients with RA. 78, 79 CCL20 preferentially recruits T H 17 cells via CC-motif chemokine receptor 6 (CCR6). 80 CCR1, CCR2, CCR5 and CCR7 are abundantly expressed in the RA synovium and on various cells in the synovial tissue.
79 CCR5 is the most prominent CC-chemokine receptor in T H 1-cell-dominated inflammatory infiltrates. 81, 82 Moreover, increased homing of CCR5 + and CXCR3 + T cells was observed in patients with seronegative arthritis, underscoring the significance of these T cell subsets in the development of the disease. 83 Expression of CCR6 on T H 17 cells, which supports the ingress of these cells into the RA joint, is attenuated by anti-TNF therapy. 80, 84, 85 CCR4 and CCR6 are expressed by both T H 17 and T REG cells, as well as on T cells with a dual T H 17/T REG -cell phenotype (Figure 1) . 66 Thus, CCR1, CCR4, CCR5, CCR6 and their ligands, CCL3, CCL5, CCL7, CCL8 and CCL20, seem to be the most relevant chemokine receptor-ligand pairs involved in T-cell recruitment to the RA joint. 78, 79 Animal models lend themselves to real-time in vivo analyses of T-cell recruitment and behaviour in lymphoid organs that are not accessible for in vivo studies in humans. For example, T-cell motility changes associated with antigen presentation, T-cell-APC interactions, and competition between antigen-experienced and naive T cells for access to antigen-bearing APCs can be visualized in real time in the joint-draining lymph nodes of mice with PGIA.
2,76,86 However, as described above, monitor ing of T-cell influx into distal joints in vivo revealed poor T-cell recruitment in these sites. 2 This limited recruitment might be a drawback of all popular mouse arthritis models when it comes to studying T cells within the joints. In addition, the small volume of synovial fluid in rodent joints and the paucity of joint-homing T cells make it difficult to isolate such T cells and study their function ex vivo.
5,8
T-cell-dependent autoantibody production RF and ACPA Probably the best-characterized autoimmune feature of RA is the presence of antibodies against self IgG (rheuma toid factor [RF]) and against citrullinated proteins (anti-citrullinated protein antibodies [ACPA]) in the sera of patients, with ACPA being more diseasespecific than RF. 87, 88 Most of these autoantibodies have undergone isotype switching, suggesting that their production by B cells requires T-cell help. 87, 89, 90 Numerous citrullinated proteins have been identified in RA synovial tissue and fluid. 87, [91] [92] [93] However, the broad epitope reper toire and the apparent lack of joint (that is, cartilage matrix protein) specificity of ACPA make it difficult to identify an 'arthritogenic' population of ACPA. Several ACPA specificities target serum proteins, such as citrullinated fibrinogen, or intracellular proteins including vimentin and α-enolase. [94] [95] [96] Although antibodies reacting with filaggrin, mutated citrullinated vimentin, and citrullinated cyclic peptides (CCP) have been used for diagnostic purposes by several laboratories, to date fibrinogen, fibrin and vimentin have been the main citrullinated proteins identified in the RA synovium. In fact, citrullinated fibrin chains are a major target of anti-filaggrin antibodies. 26 It has been demonstrated that epitope spreading of ACPA starts in the preclinical phase of RA, and is, at least in part, responsible for the perpetuation of the disease. 94 Moreover, ACPA fine-specificities have been associated with clinical responses to biologic agents in patients with RA. 95 However, as mentioned above, arthritogenic ACPA specificities have not yet been eluci dated, although the synovial T-cell repertoire is quite different in ACPA-positive and ACPA-negative sub sets of patients with RA. For example, an altered distribu tion of TCR complementarity-determining region 3 (CDR3) lengths, which is associated with monoclonal or oligoclonal T-cell expansion, was detected more frequently in ACPA-positive than ACPA-negative RA, suggesting the preferential involvement of clonally expanded T cells in seropositive disease. 97 In animal models, ACPA responses to intracellular proteins develop during the early stages of CIA, and mice with chronic CIA exhibit expansion of antibody reactivity against citrullinated peptides.
98 Both ACPA and RF are produced in PGIA, which makes this model, as well as human aggrecan G1-domain-induced arthritis, 99 more relevant to seropositive RA than other mouse models, and also a suitable model for investigating the potential pathogenic role of ACPA in RA development.
Other autoantibodies T-cell-B-cell crosstalk is clearly involved in autoantibody production in various mouse models of RA. In CIA, autoantibodies of the IgG2 isotype that crossreact REVIEWS with mouse CII have been shown to cause chondrocyte death in the presence of complement; 21 thus, T-cell help in switching to the IgG2 isotype is crucial for producing pathogenic antibodies that can mediate cell death. As mentioned above, citrullinated-fibrinogen-specific T cells transferred to mice with CIA enhanced the production of anti-CII autoantibodies, providing further evidence of T-cell-B-cell crosstalk. 27 These findings might also be of relevance to human disease, as anti-CII antibodies have been detected in patients with early RA. 100 In PGIA, antibodies against mouse proteoglycan are generated after the second immunization with human proteoglycan, and the progression from anti-human to self-reactive anti-mouse proteoglycan antibodies correlates with the development of arthritis. 8 IgG-containing deposits are detected in the joints before arthritis onset, indicating that the formation of complement-fixing immune complexes containing proteoglycan and antiproteoglycan antibodies might be the primary event that initiates the local activation of synovial macrophages and fibroblasts and the recruitment of leukocytes, which collectively drive inflammation and tissue destruction. 7, 8 T cells are involved in the initiation of B-cell activation and auto antibody production, as well as the maintenance of au toimmunity throughout the disease course.
In K/BxN arthritis, linked T-cell and B-cell recognition of G6PI leads to overproduction of self-reactive anti-G6PI antibodies. 22 It has been suggested that immune complexes formed inside the joints of K/BxN mice can fix complement and activate Fc receptors, thereby initiating leukocyte recruitment as well as local inflammatory mediator production. 22 However, although treatment of K/BxN mice expressing human CD20 with the anti-human-CD20 antibody rituximab markedly reduced serum levels of anti-G6PI antibodies, it failed to suppress arthritis, suggesting that the level of circulating autoantibodies does not necessarily correlate with disease severity. On the other hand, transfer of arthritic K/BxN serum to naive mice can induce disease in a wide range of mouse strains, including B-cell-deficient or lymphocyte-deficient hosts, via G6PI-specific autoantibodies. 22, 101 However, passive induction of arthritis is not a universal phenomenon, as serum from mice rendered arthritic by immunization with G6PI, 14 or from other models including PGIA, 102 cannot transfer disease. This finding indicates that a certain threshold level of auto antibodies, perhaps of a particular antigen specificity and isotype, in the circulation might be required for arthritis induction. Although inflammation induced by arthritic K/BxN serum transfer recapitulates the major histopathological features of disease seen in the donor mice, arthritis is transient. Inflammation declines 2 weeks after serum transfer, and previously swollen joints show little or no evidence of inflammation or cartilage destruction. Arthritis transience can be overcome by repeated injections of serum from arthritic K/BxN mice, suggesting that a continuous supply of even the most potent autoantibodies is necessary for sustained inflammation. 22 Although arthritis cannot be transferred via serum injection in the PGIA model, administration of immune sera accelerates the development of arthritis induced by ly mphocyte transfer. 102 In conclusion, the production of autoantibodies, including ACPA and RF, is characteristic of both RA and mouse arthritis, but among the mouse models ACPA and RF are produced concurrently only in PGIA. ACPA speci ficities may differ substantially between RA and animal models. Antibodies to citrullinated fibrinogen (and perhaps other, unknown antigens) might have a central role in humans and mice. Transferability of arthritis by autoantibody-containing sera to naive mice (which certainly cannot be tested in humans) might challenge the current paradigm regarding a direct contribution of joint-homing T cells to arthritis initiation.
Therapeutic targeting of T cells
Therapies targeting T cells in RA have held great promise since the 1990s. Several anti-CD4, anti-CD5, anti-CD7 and anti-CD52 antibodies have been developed and tested, but no clear-cut clinical efficacy could be demon strated in clinical trials, and no correlation has been found between antibody-induced T-cell depletion and disease status in RA. 103 To date, only one strategy of T-cell inhibition-blockade of signalling through the co-stimulatory molecule CD28 using a CTLA4-Ig fusion protein known as abatacept-has shown efficacy in clinical trials, leading to the registration of abatacept for the treatment of RA. 104 With regard to indirect T-cell blockade, B-cell inhibition by the anti-CD20 antibody rituximab also affects T cells. Rituximab administration might decrease the activated phenotype of peripheral and tissue-resident T cells by abolishing antigen presentation by B cells. 105 Much controversy has surrounded the effect of B-cell blockade on T REG cells. Rituximab treatment might enhance the numbers and function of these cells; 105 however, in another study, anti-CD20 therapy did not influence the frequency of T REG cells in RA. 106 Finally, a CD20 + T-cell subset has been characterized and shown to comprise terminally differentiated T cells with immunoregulatory and proinflammatory properties. Rituximab also depleted this T-cell population, an effect that might have a role in the beneficial effects of B-cell targeting in RA (Table 1) . 107 As CC chemokines and their receptors have been implicated in T-cell homing to the joint, we briefly touch on the efficacy of chemokine receptor blockade. To date, antibody-mediated blockade of CCR2 and CCR5 has yielded disappointing results in RA, and variable outcomes have been reported for CCR1 blockade. How ever, the fact that CC-chemokine receptor blockade failed in most clinical trials does not necessarily mean that chemokine receptors are not legitimate targets in RA. Rather, it seems to be critical to achieve very high levels of receptor occupancy to continuously inhibit leukocyte migration into the synovial compartment. 79, 108 Of note, patients with RA treated with TNF antagonists exhibit low expression levels of CCR6 in T H 17 cells and reduced proportions of these cells in the joints. 85 In contrast to RA, numerous T-cell-targeting therapies using anti-CD4 antibodies or genetic manipulations have shown great efficacy in preventing arthritis in animals, including in the PGIA, 11 CIA 12 and K/BxN 22 models. There might be important reasons for this discrepancy. RA is characterized by a 'waxing and waning' of disease symp toms, and a persistence of polyclonally or oligoclonally expanded T cells including self-reactive populations. By contrast, arthritis is 'monophasic' in most rodent models, and joint inflammation is preceded by a robust and single-antigen-focused T-cell response, only a part of which is directed against self. It is relatively easy, therefore, to prevent arthritis in animal models by deleting T cells or knocking out molecules essential for the effector function of T cells. The early involvement of T cells in arthritis also means that anti-CD4 treatment works best when applied preventatively, before the appearance of clinical symptoms.
12 In the CIA model, anti-CD4 treatment administered after arthritis onset failed to suppress disease or eliminate the CII-reactive pathogenic population of T cells, 12 which might, in part, explain the inefficacy of a similar treatment in established RA. In addition, in the majority of animal models, counter-regulatory mechanisms mainly involving innate immune cells such as joint-infiltrating myeloid-derived suppressor cells 109 kick in early during the course of inflammation. These innate immune cells can effectively reduce T-cell responses and inflammation in a reasonably short period of time, thereby masking the potentially beneficial effects of T-cell-targeting therapeutics administered after disease onset ( Table 1) .
As indicated by the clinical success of abataceptmediated blockade of T-cell co-stimulation, 104 treatment strategies that indirectly influence T cells may be more effective in RA than antibody-induced depletion or neutralization of these cells. For example, as mentioned above, adoptive transfer of CD25 + T REG cells and T REG -cell-inducing BMT suppressed ongoing CIA 63 and PGIA, 64 respectively, suggesting that in vivo induction or transfer of ex vivo-induced autologous T REG cells could be an effective therapy in RA. B-cell depletion via anti-CD20 antibody administration, which is also highly effective in RA, not only reduced T-celldependent autoantibody production in PGIA and the K/BxN model, 37, 68 but also diminished proteoglycanspecific T-cell responses and increased T REG -cell activity in PGIA. 37 These animal studies suggest that B-cell depletion via rituximab in RA probably has an indirect effect on T cells by shifting the balance between pathogenic and suppressive subsets in favour of suppressive T REG cells.
In summary, the inefficacy of T-cell depletion in RA may be explained by differences between RA and mouse arthritis in disease course as well as in the potency or persistence of autoreactive T cells. Even in mouse models, anti-CD4 treatment works only when initiated before the onset of arthritis, and not in established disease. Animal studies suggest that therapies that restore or stabilize the number and suppressive function of T REG cells are the key to further success in the treatment of RA.
Conclusions
It is widely accepted that autoreactive T cells have a major role in the pathogenesis of RA as well as in a number of animal models of the human disease. MHC-restricted autoreactive T-cell responses and T-cell-dependent autoantibody production have been extensively characterized in both species. However, the specific contribution of T cells to joint inflammation is not clear in either RA or mouse models of arthritis. Despite similarities in T-cell subset composition, differences exist between humans and mice in the cytokine regulation of T H -cell polarization, the developmental plasticity of T cells, and the T H 17 cell-T REG cell axis. Finally, whereas most T-cell depletion strategies have failed in RA, elimination of T cells has prevented or suppressed arthritis in numerous animal models. In conclusion, although animal models such as PGIA or CIA bear considerable resemblance to the human disease, additional studies are needed to refine our understanding of T-cell pathology in autoimmune arthritis and to further enhance the value of pre clinical animal studies in predicting the outcome of T-cell-focused therapeutic interventions in RA.
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